TITLE

Clinical Pharmacokinetics and Administration of Established Platinum Drugs

AUTHOR(S)
O'Dwyer, P.J.; Stevenson, J.P.; Johnson, S.W.
PUB. DATE
June 2000
SOURCE
Drugs;Jun2000 Supplement 4, Vol. 59 Issue 6, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We review the pharmacology and clinical administration of the commonly used platinum-based anticancer drugs cisplatin and carboplatin, and the more recently approved diamminocyclohexane-based oxaliplatin. The development of analogues of cisplatin has been focused upon identifying compounds with less toxicity and with a different spectrum of activity. Carboplatin exemplifies the former, while the initial data with oxaliplatin support its activity in cisplatin-resistant tumours. The clinical pharmacokinetics of the drugs are reviewed. Incorporation of these data into the design of clinical regimens has permitted individualised therapy with carboplatin, and has enhanced safety. Additional investigation of the pharmacodynamics of all of these agents is expected to result in their selective application. The clinical effects of these analogues are discussed.
ACCESSION #
9593677

 

Related Articles

  • paclitaxel.  // Davis's Drug Guide for Nurses, 10th edition;2007, p909 

    This article presents information on the drug paclitaxel, which is marketed as Onxol and Taxo. This drug is classified as antineoplastics and pharmacologically falls under taxoids. It is used to treat advanced ovarian cancer together with cisplatin. Information on adverse reactions,...

  • Clinical and preclinical pharmacokinetics of raltitrexed. Clarke, S.J.; Beale, P.J.; Rivory, L.P. // Clinical Pharmacokinetics;2000, Vol. 39 Issue 6, p429 

    Raltitrexed is a specific, folate-based inhibitor of thymidylate synthase with activity in advanced colorectal cancer comparable with that of fluorouracil (5-fluorouracil) plus folinic acid. Its activity is enhanced by rapid cellular entry and polyglutamation, with the polyglutamated derivatives...

  • Low dose–high dose: what is the right dose? Pharmacokinetic modeling of etoposide. Würthwein, Gudrun; Boos, Joachim // Cancer Chemotherapy & Pharmacology;Apr2002, Vol. 49 Issue 4, p303 

    Purpose: Some clinical studies on etoposide (Eto) have shown marked schedule dependency of the effect (starting at about 1 mg/l) and toxicity (over about 10 mg/l) whereas other studies have not confirmed these results. What are the conclusions we can draw from these inconsistent results when...

  • Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics. Smith, N. F.; Marsh, S.; Scott-Horton, T. J.; Hamada, A.; Mielke, S.; Mross, K.; Figg, W. D.; Verweij, J.; McLeod, H. L.; Sparreboom, A. // Clinical Pharmacology & Therapeutics;Jan2007, Vol. 81 Issue 1, p76 

    To explore retrospectively the relationships between paclitaxel pharmacokinetics and three known, non-synonymous single-nucleotide polymorphisms (SNPs) in SLCO1B3, the gene encoding organic anion transporting polypeptide (OATP)1B3. Accumulation of [3H]paclitaxel was studied in Xenopus laevis...

  • A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers. Cantarini, Mireille V.; Macpherson, Merran P.; Marshall, Anna L.; Robinson, Anna V.; Bailey, Christopher J. // Cancer Chemotherapy & Pharmacology;Dec2005, Vol. 56 Issue 6, p557 

    Objectives: To determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy volunteers.Methods: An open-label, single-center, phase I study in healthy male volunteers. Each volunteer received a single 250 mg...

  • Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Siegel-Lakhai, W. S.; Crul, M.; Zhang, S.; Sparidans, R. W.; Pluim, D.; Howes, A.; Solanki, B.; Beijnen, J. H.; Schellens, J. H. M. // British Journal of Cancer;11/28/2005, Vol. 93 Issue 11, p1222 

    This phase I trial was designed to determine the safety and maximum tolerated dose (MTD) of tipifarnib in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Furthermore, the pharmacokinetics of each of these agents was evaluated. Patients were treated with...

  • Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. Rassnick, Kenneth; Muindi, Josephia; Johnson, Candace; Bailey, Dennis; Trump, Donald // Cancer Chemotherapy & Pharmacology;Jan2011, Vol. 67 Issue 1, p165 

    Purpose: High-dose calcitriol (1,25-dihydroxyvitamin D) has antineoplastic activity against a range of tumors and potentiates chemotherapeutic agents. In an earlier canine study, the MTD of intravenous (i.v.) calcitriol was 3.75 μg/kg, but polysorbate-associated hypersensitivity reactions...

  • Population pharmacokinetics of cisplatin in adult cancer patients. de Jongh, Felix E.; Gallo, James M.; Shen, Meiyu; Verweij, Jaap; Sparreboom, Alex // Cancer Chemotherapy & Pharmacology;Aug2004, Vol. 54 Issue 2, p105 

    Purpose: To characterize the pharmacokinetics of the anticancer agent cisplatin, and explore the influence of patient covariates and interoccasion variability on drug disposition. Methods: Data were obtained from 285 patients (519 complete curves; 3483 plasma samples) who received the drug as a...

  • Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility. Abe, Satoshi; Tokizaki, Toru; Miki, Yuji; Tateishi, Akio; Ogawa, Kazuhiko; Nakano, Hirotaka; Matsushita, Takashi // Cancer Chemotherapy & Pharmacology;Jul2005, Vol. 56 Issue 1, p55 

    The objectives of this study were to investigate the pharmacokinetics of cisplatin (CDDP) and the thermal dose, toxicity, and feasibility of hyperthermic isolated regional perfusion (HIRP) with CDDP for bone and soft-tissue sarcomas of the lower limb. A total of 43 patients were treated with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics